Remnant Cholesterol Could Be Redefining Metabolic Management for Pharmacists

A recent investigation published in Diabetes, Metabolic Syndrome, and Obesity is shedding new light on how different insulin regimens influence remnant cholesterol (RC), a nonconventional lipid marker that is increasingly recognized as an indicator of residual cardiovascular risk in patients with type 2 diabetes (T2D). Although pharmacists have traditionally focused on hemoglobin A_1c and low-density lipoprotein (LDL-C) targets, the study suggests that the choice of insulin regimen, specifically the transition from basal-only to combined basal-prandial therapy, may play a significant role in managing the broader metabolic profile of diabetic patients.¹

“Despite growing recognition of remnant cholesterol as an important marker of residual cardiovascular risk, most clinical studies have focused on conventional lipid parameters and the influence of different insulin regimens on remnant cholesterol levels remains poorly understood,” the study authors said.¹

The research, which followed 118 patients with T2D, found that those utilizing a combined basal-prandial insulin regimen were significantly more likely to maintain normal RC levels compared to those on basal insulin alone, with 49.2% of the combination group reaching healthy targets compared with only 30.5% in the basal group.¹

Pharmacists must understand that RC represents the cholesterol content within triglyceride-rich lipoproteins that remain after lipolysis, and it is easily calculated from a standard lipid panel by subtracting both high-density lipoprotein (HDL-C) and LDL-C from total cholesterol. This marker is particularly relevant because these remnant particles are cholesterol-rich and can penetrate the vascular intima to trigger inflammation and plaque formation even when LDL-C is controlled.^1,2

The physiological rationale for the superior performance of combined regimens lies in their ability to mimic endogenous insulin secretion. Although basal insulin effectively suppresses hepatic glucose production during fasting, it often fails to control postprandial glucose spikes. These spikes are major contributors to hepatic lipogenesis and the production of very low-density lipoprotein, which directly increases RC levels. In contrast, the addition of prandial insulin targets postprandial fluxes, reducing the availability of lipogenic substrates and accelerating the clearance of remnant particles by increasing lipoprotein lipase activity.¹

The clinical importance of monitoring RC extends beyond patients with established diabetes. Data from a large-scale analysis of US adults indicates a significant nonlinearrelationship between RC levels and diabetes prevalence, identifying a critical threshold at 19 mg/dL. Below this inflection point, every 1 mg/dL increase in RC is associated with a 45.9% higher odd of having diabetes, highlighting RC as a potent metabolic marker that may precede overt diagnosis. Furthermore, longitudinal data suggests that RC is a unique predictor for the development of T2D in patients with nonalcoholic fatty liver disease (NAFLD).^2,3

“Typical dyslipidemia is common in both NAFLD and diabetes,” the study authors said.² “However, in recent years, increasing attention has been given to nonconventional lipid parameters, such as remnant cholesterol.”

In these patients, high baseline RC was associated with a 1.68-fold greater risk of incident diabetes over a 12-year follow-up, a correlation that was notably absent in individuals without fatty liver disease. This suggests that pharmacists managing patients with NAFLD should be particularly vigilant regarding their lipid handling, as reduced lipoprotein lipase activity in these individuals may exacerbate the accumulation of atherogenic remnants.³

Despite the clear descriptive benefits of combined insulin regimens, the current study also offers a cautionary note for clinical practice as the insulin regimen itself may not be an independent driver of RC levels. When researchers adjusted for other factors, the statistical significance of the regimen type vanished, revealing that overall metabolic burden plays a more dominant role. Specifically, the duration of diabetes and body mass index were found to have the strongest influence on the association between insulin type and RC levels. Most strikingly, normal HDL-C levels remained the most powerful independent protective factor, with patients having a 4.9 times greater chance of maintaining healthy RC regardless of their insulin type.¹

For the pharmacist, these findings emphasize that insulin management should not be viewed in a vacuum of glycemic control alone. Although transitioning a patient to a basal-prandial regimen such as insulin degludec/aspart may improve their lipid metabolic milieu, the most effective interventions will likely be those that address the patient's holistic metabolic risk profile, including adiposity and lipid metabolism.¹

RC is emerging as a valuable biomarker for evaluating the effectiveness of these comprehensive strategies, providing a more nuanced view of the atherosclerotic and cardiovascular risks that persist even after traditional targets are met. As diabetes prevalence continues to grow globally, the ability to interpret these nonconventional lipid markers will be a vital tool for pharmacists in preventing long-term complications through personalized and biologically plausible therapeutic adjustments.¹

READ MORE: Insulin Management Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Natsir RM, Halimah E, Diantini A, Levita J, Umar H. Comparative Association of Basal and Basal-Prandial Insulin Regimens on Remnant Cholesterol and Lipid Profiles in Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2026;19:588522. Published 2026 Mar 12. doi:10.2147/DMSO.S588522

2. Yang L, Huang H, Wang Z, Xu C. Remnant cholesterol predicts the development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Diabetol Metab Syndr. 2025;17(1):277. Published 2025 Jul 18. doi:10.1186/s13098-025-01828-z

3. Li X, Cui G, Wang X. A cross-sectional analysis of remnant cholesterol-diabetes association in US adults. Sci Rep. 2025;15(1):26572. Published 2025 Jul 22. doi:10.1038/s41598-025-10961-8